The HEDIMED project aims to identify the exposomic determinants that are driving the rapid increase of immune-mediated diseases (IMDs) such as type 1 diabetes, celiac disease, allergies and asthma. The project uses data and samples from unique large clinical cohorts and trials from countries with both high and low IMD incidence.
Published in June 2022, the HEDIMED profile paper outlines the project’s focus on common, chronic immune-mediated diseases.
A full list of scientific publications linked to the project is available here.
Click here for the full list of public deliverables.
Tampere University, Finland (Project Coordination)
Baylor College of Medicine, USA
Charles University, Czech Republic
Copenhagen Prospective Studies on Asthma in Childhood, Denmark
Czech University of Life Sciences Prague, Czech Republic
Empirica MBH, Germany
Finnish National Institute for Health and Welfare (THL), Finland
Gnomon Informatics SA, EL
Graz University of Technology, Austria
Lund University, Sweden
Natural Resources Institute, Finland
Norwegian Institute of Public Health, Norway
Pirkanmaa Hospital District, Finland
Satellio Oy, Finland
Swiss Center for Electronics and Microtechnology (CSEM SA)
Tartu University Clinic, Estonia
University of Helsinki, Finland
University of Oulu, Finland
University of Siena, Italy
University of Tartu, Estonia
University of Turku, Finland
VTT Technical Research Centre, Finland
